Brief: Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics
12/02/2026 14:02
Feb 12 (Reuters) - Aprea Therapeutics Inc APRE.O: APREA THERAPEUTICS STRENGTHENS GLOBAL PATENT PORTFOLIO IN DNA DAMAGE RESPONSE (DDR) CANCER THERAPEUTICS, PAVING WAY FOR PIPELINE GROWTH APREA THERAPEUTICS INC - GRANTED NEW PATENTS IN AUSTRALIA AND JAPAN APREA THERAPEUTICS INC - CORE PATENT FAMILIES EXPECTED TO PROVIDE EXCLUSIVITY INTO 2045 APREA THERAPEUTICS INC - EXISTING ISSUED PATENTS EXPECTED TO REMAIN IN FORCE THROUGH 2035-2037 Source text: ID:nGNX7Tpb4K Further company coverage: APRE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aprea Therapeutics
See all newsAprea Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aprea Therapeutics Q2 net loss widens on higher R&D costs
Aprea Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview
Brief: Aprea Therapeutics Provides Acesot-1051 Program Update For Wee1 Inhibitor Apr-1051 Accelerating And Expanding Enrollment. Clinical Data Presentation Planned For Q4 2026
Brief: Aprea Therapeutics - Files For Resale Of Up To 5.5 Million Shares By Selling Stockholders - SEC Filing